SCHEMBL6411635

SCHEMBL6411635

COC(=O)/C(O)=C/C(=O)N(Cc1ccc(F)cc1)Cc1ccc(F)c(F)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.40
CA12 O43570 2/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA9 Q16790 1/20 0.39
RIPK1 Q13546 1/20 0.39
PSEN1 P49768 1/20 0.39
PSEN2 P49810 1/20 0.39
APH1B Q8WW43 1/20 0.39
NCSTN Q92542 1/20 0.39
APH1A Q96BI3 1/20 0.39
PSENEN Q9NZ42 1/20 0.39
HTT P42858 2/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MITF O75030 1/20 0.39
BMP1 P13497 1/20 0.37
EGFR P00533 2/20 0.36
ERBB2 P04626 1/20 0.36
CA4 P22748 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6411640 1.00 PTPN1 (0.40) PTPN1CA12CA1CA2CA9
SCHEMBL6076667 0.91 CA12 (0.44) CA12CA1CA2CA9RIPK1
SCHEMBL6076664 0.91 CA12 (0.44) CA12CA1CA2CA9RIPK1
SCHEMBL6414935 0.88 BCL2A1 (0.48) CA12CA1CA2CA9EGFR
SCHEMBL6414940 0.88 BCL2A1 (0.48) CA12CA1CA2CA9EGFR
SCHEMBL6077524 0.86 RIPK1 (0.40) CA12CA1CA2CA9RIPK1
SCHEMBL6077521 0.86 RIPK1 (0.40) CA12CA1CA2CA9RIPK1
SCHEMBL6412472 0.86 ALDH1A1 (0.48) CA12CA1CA2CA9ALDH1A1
SCHEMBL6412466 0.86 ALDH1A1 (0.48) CA12CA1CA2CA9ALDH1A1
SCHEMBL6412651 0.86 ALDH1A1 (0.46) CA12CA1CA2CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043370-A1 HIV integrase inhibitors WALKER MICHAEL A (US) 2005-02-24 US disclosed
US-6803378-B2 FOR THERAPY AND PROPHYLAXIS OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), OR ARC BRISTOL-MYERS SQUIBB COMPANY 2004-10-12 US disclosed
US-20030181490-A1 HIV integrase inhibitors WALKER MICHAEL A (US) 2003-09-25 US disclosed
US-20030027847-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2003-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043370-A1 HIV integrase inhibitors AKR1C3, CBR3, CBR1 PTPN1 3176/4885CA12 4631/4885CA1 4495/4885
US-20030181490-A1 HIV integrase inhibitors CBR1, CCR5, CCR1 PTPN1 2115/4885CA12 4781/4885CA1 4643/4885
US-20030027847-A1 HIV integrase inhibitors CBR1, CCR5, CCR1 PTPN1 2115/4885CA12 4781/4885CA1 4643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.